"CRISPR Faces Regulatory Delays, Approval Timeline Uncertain"

The FDA's recent approval of Casgevy, a CRISPR gene-editing therapy for sickle cell anemia, marks a historic milestone, but a report by GlobalData suggests that further approvals for similar CRISPR-based drugs are not expected soon. With only 24 CRISPR drugs in Phase 2 trials and the majority in early-stage development, the pipeline for these therapies is relatively immature. CRISPR Therapeutics' CTX-110 is identified as the next potential candidate for approval, possibly by the end of 2025, but it faces uncertain prospects. The company has shifted focus to other therapies, indicating ongoing development and evaluation within the CRISPR drug landscape.